SLC45A4 and prostate carcinoma: The chimeric fusion SLC45A4‐ELK4 transcript was identified in prostate cancer, but further study revealed that SLC45A4‐ELK4 functions as a lncRNA to promote prostate cancer cell proliferation.[6] In addition, ELK4 has been reported to activate the proto‐oncogene c‐fos[7] and the antiapoptotic protein Mcl‐1[8] to maintain the malignant phenotype in melanoma and promote tumor formation in glioblastoma, respectively.